Global Drug Device Combination Market Segmentation, By Product (Auto-Injectors, Infusion Pumps, Photosensitizers , Woundcare Combination Products , Transdermal Patches , Microneedle Patches, Digital Pills, Smart Inhalers, Drug Delivery Hydrogels, Drug-Eluting Lenses, and Others) Application Type (Orthopedic Diseases, Respiratory Diseases, Diabetes, Oncology, Cardiovascular Diseases, and Others), End User (Clinics, Hospitals, Home Care Settings, Ambulatory Care Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) – Industry Trends and Forecast to 2031.
Drug Device Combination Market Analysis
The drug-device combination market is experiencing strong growth, with advancements in drug delivery technologies and the increasing prevalence of chronic diseases such as cardiovascular conditions, diabetes, and cancer driving demand. Key innovations such as bioresorbable stents, which dissolve after serving their purpose, and microneedle drug patches, offering painless, targeted delivery, are significantly improving treatment precision and patient outcomes. The rise in personalized medicine, especially in oncology, and the use of combination therapies that integrate drugs with implantable devices continue to push market expansion. Regulatory bodies such as the U.S. FDA’s Combination Products Policy Council and the European Medicines Agency’s (EMA) tailored pathways for combination products are expediting approval processes, enabling faster market entry for new technologies.
Drug Device Combination Market Size
The global drug device combination market size was valued at USD 15.63 billion in 2023 and is projected to reach USD 34.00 billion by 2031, with a CAGR of 10.20% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Drug Device Combination Market Trends
“Increasing Use of Smart Drug Delivery Systems”
Trending smart drug delivery systems, such as Propeller Health’s connected inhalers and Tandem Diabetes’ tX2 insulin pump, are revolutionizing chronic disease management by integrating medication administration with real-time digital tracking. Such devices connect to apps that allow patients to monitor their medication use and health data, offering valuable feedback for both patients and healthcare providers. For instance, Propeller's inhalers track asthma medication usage and alert users to environmental triggers, improving adherence and management. Similarly, the tX2 insulin pump adjusts insulin delivery based on continuous glucose data, ensuring more precise and personalized treatment for diabetes patients. Such technology-driven approach is improving patient outcomes and reducing hospitalizations by promoting proactive disease management.
Report Scope and Drug Device Combination Market Segmentation
|
Attributes
|
Drug Device Combination Key Market Insights
|
|
Segments Covered
|
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Key Market Players
|
Medtronic (Ireland), Zimmer Biomet (U.S.), Amgen Inc. (U.S.), Mediprint Apparatebau GmbH (U.S.), Propeller Health (U.S.), BD (U.S.), CosMED Pharmaceutical Co., Ltd (Japan), Micron Biomedical, Inc. (U.S.), Findair Sp. z o. o. (Poland), MetP Pharma AG (Switzerland), Sonceboz (Switzerland), Eitan Medical (Israel), Vaxess Technologies Inc. (U.S.), GSK plc (U.K.), Bayer AG (Germany), NanoPass (Israel), Sensirion AG (Switzerland), Janssen Global Services, LLC (U.S.), Insulet Corporation (U.S.), TheraJect (U.S.), Otsuka America Pharmaceutical, Inc. (U.S.), EOFLOW CO., LTD. (South Korea), CGbio (South Korea).
|
|
Market Opportunities
|
|
|
Value Added Data Infosets
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Drug Device Combination Market Definition
A drug-device combination is a product that integrates a pharmaceutical drug with a medical device, designed to deliver the drug to the patient in a controlled and effective manner. Such combinations can enhance the therapeutic benefits of the drug while providing convenience and precision in administration. For instance, Insulin pumps, which deliver insulin to manage diabetes, and inhalers equipped with sensors that track medication use. The integration of the drug and device components ensures that the medication is administered correctly and that the device supports the intended therapeutic outcomes.
Drug Device Combination Market Dynamics
Drivers
- Rising Prevalence of Chronic Diseases
The rising prevalence of chronic diseases, such as cardiovascular conditions, diabetes, and cancer, is a major driver of the drug-device combination market, as these conditions require long-term management and precise treatment. For instance, according to the World Health Organization (WHO), cardiovascular diseases are the leading cause of death globally, responsible for an estimated 17.90 million deaths annually. Such statistics underscore the need for innovative treatment solutions. Drug-device combinations, such as drug-eluting stents for heart disease and insulin pumps for diabetes, offer targeted and sustained drug delivery, enhancing treatment efficacy and improving patient compliance. The growing burden of such chronic conditions is pushing healthcare providers and patients to seek more effective, integrated solutions, thereby boosting demand for drug-device combinations that offer both convenience and improved health outcomes.
- Growth of Personalized Medicine
The growth of personalized medicine is significantly driving the development of tailored drug-device combinations, especially in oncology. Such shift is exemplified by the use of personalized drug-delivery systems that cater to individual patient profiles, enhancing treatment precision and efficacy. For instance, The Kymriah therapy by Novartis, which involves genetically modifying a patient’s own T cells to target cancer cells more effectively. Such therapy is paired with specialized infusion devices to ensure precise administration and monitoring. Additionally, the integration of advanced biomarker profiling and genetic testing helps in creating bespoke treatment plans, which are tailored to the unique genetic and molecular characteristics of each patient's cancer. Such approach not only improves the effectiveness of treatments but also minimizes adverse effects, setting a new standard for personalized oncology care. As a result, the personalized medicine trend is driving significant advancements in drug-device combinations, paving the way for more targeted and effective cancer therapies.
Opportunities
- Rise in Ageing Population
The aging global population is significantly boosting the demand for long-term disease management solutions, and drug-device combinations are well-suited to address this need. According to the United Nations, the number of people aged 60 and older is projected to reach 2.1 billion by 2050, representing a substantial increase in the prevalence of age-related chronic conditions. Apparent demographic shift is driving demand for innovative products such as continuous glucose monitoring systems and advanced pacemakers. For instance, the Dexcom G6 continuous glucose monitoring system, which combines a wearable sensor with real-time glucose tracking, has become increasingly popular among older adults managing diabetes. Such drug-device combinations not only improve the quality of life for aging individuals but also offer practical solutions for managing chronic conditions over the long term.
- Rising Demand for Minimally Invasive Procedures
The rising demand for minimally invasive procedures is profoundly influencing the drug-device combination market, as these products provide less invasive alternatives that facilitate quicker recovery and shorter hospital stays. Minimally invasive techniques, such as those involving drug-eluting stents and advanced endoscopic systems, are increasingly preferred for their ability to reduce surgical trauma and improve patient outcomes. For instance, drug-eluting stents, which release medication to prevent the re-narrowing of arteries, have been shown to decrease the need for repeat procedures and minimize recovery time. Such growing preference for minimally invasive approaches not only enhances patient comfort and safety but also contributes to overall healthcare efficiency, driving the continued expansion and innovation within the drug-device combination market.
Restraints/Challenges
- Complex Intellectual Property Rights
Intellectual property concerns are particularly significant in the drug-device combination market, where protecting innovations involves navigating a complex landscape of patents and potential infringement disputes. For instance, Medtronic’s recent approval of its MiniMed 780G insulin pump, a drug-device combination, highlights the challenges in securing IP. The company has invested heavily in patenting its technology to safeguard its innovations against competitors. However, patent disputes are common, as evidenced by a 2023 lawsuit where a rival company, Tandem Diabetes, challenged Medtronic’s patent claims, alleging that their technology infringed on existing patents. Such disputes can lead to costly legal battles and potentially hinder market entry for new players.
- Rising Supply chain complexities
Supply chain complexities are a significant challenge in the drug-device combination market due to the need to coordinate multiple suppliers and manufacturers. For instance, the production of insulin delivery systems, such as the Tandem Diabetes tX2 insulin pump, involves sourcing components from various global suppliers, including electronic components, drug reservoirs, and infusion sets. Managing this intricate supply chain is critical to ensure timely delivery and product quality. In 2022, Tandem faced disruptions when a key supplier for electronic components experienced delays, impacting the production schedule and leading to shortages in the market. Such situations highlighted the vulnerability of the supply chain in the drug-device sector, where any delay or disruption can have cascading effects on manufacturing timelines, product availability, and ultimately, patient care. Consequently impeding the drug-device combination market.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Drug Device Combination Market Scope
The market is segmented on the basis of products, application types, end users, and distribution channels. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Auto-Injector
- Infusion Pumps
- Implantable Infusion Pumps
- Ambulatory Infusion Pumps
- Photosensitizers
- Woundcare Combination Products
- Transdermal Patches
- Microneedle Patch
- Digital Pill
- Smart Inhaler
- Metered Dose Inhalers
- Dry Powder Inhalers
- Nebulizers
- Drug Delivery Hydrogels
- Drug-Eluting Lens
- Coronary Stents
- Peripheral Vascular Stents
- Others
- Intraocular Implants
- Drug Eluting Beads
Application Type
- Orthopedic Diseases
- Respiratory Diseases
- Diabetes
- Oncology
- Cardiovascular Diseases
- Others
End User
- Clinics
- Hospitals
- Home Care Settings
- Ambulatory Care Centers
- Others
Distribution Channel
- Direct Tender
- Retail Sales
- Others
Drug Device Combination Market Regional Analysis
The market is analysed and market size insights and trends are provided by country, products, application types, end users, and distribution channels as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to capture a significant share of the global drug-device combination market. This is due to the region's strong healthcare infrastructure, increased awareness of drug-device combinations, and their widespread use. Additionally, the high prevalence of chronic conditions further drives market growth, positioning North America as a major force in this advancing healthcare sector.
The Asia-Pacific region is expected to be the fastest-growing market in the global drug-device combination sector from 2024 to 2031. This rapid growth is driven by its large population, increasing adoption of advanced technologies, rising demand for personalized medicine, and a higher incidence of chronic diseases. As a result, Asia-Pacific is becoming a crucial player in the evolving field of drug-device combination products.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Drug Device Combination Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Drug Device Combination Market Leaders Operating in the Market Are:
- Medtronic (Ireland)
- Zimmer Biomet (U.S.)
- Amgen Inc. (U.S.)
- Mediprint Apparatebau GmbH (Germany)
- Propeller Health (U.S.)
- BD (U.S.)
- CosMED Pharmaceutical Co., Ltd (Japan)
- Micron Biomedical, Inc. (U.S.)
- Findair Sp. z o. o. (Poland)
- MetP Pharma AG (Switzerland)
- Sonceboz SA (Switzerland)
- Eitan Medical (Israel)
- Vaxess Technologies Inc. (U.S.)
- GSK plc (U.K.)
- Bayer AG (Germany)
- NanoPass (Israel)
- Sensirion AG (Switzerland)
- Janssen Global Services, LLC (U.S.)
- Insulet Corporation (U.S.)
- TheraJect (U.S.)
- Otsuka America Pharmaceutical, Inc. (U.S.)
- EOFLOW CO., LTD. (South Korea)
- CGbio (South Korea)
Latest Developments in Drug Device Combination Market
- In December 2022, Terumo Corporation introduced the G-Lasta Subcutaneous Injection 3.6 mg BodyPod, a drug-device combination product developed in collaboration with Kyowa Kirin Co., Ltd. The product received approval from Japan's Ministry of Health, Labour, and Welfare (MHLW).
- In March 2024, SHL partnered with Swiss CDMO ten23 to offer comprehensive services for companies needing sterile drug-device combination products. This collaboration merges ten23's expertise in contract development and manufacturing with SHL Medical's advanced autoinjector device technology.
SKU-